Masakiyo Hosokawa

List of Publications by Year
in descending order

80 papers	5,030 citations	136950 32 h-index	95266 68 g-index
83 all docs	83 docs citations	83 times ranked	3919 citing authors

#	Article	IF	Citations
1	Effects of steric hindrance and electron density of ester prodrugs on controlling the metabolic activation by human carboxylesterase. Drug Metabolism and Pharmacokinetics, 2021, 38, 100391.	2.2	4
2	Structure-activity relationship of atorvastatin derivatives for metabolic activation by hydrolases. Xenobiotica, 2020, 50, 261-269.	1.1	11
3	Investigation of the chiral recognition ability of human carboxylesterase 1 using indomethacin esters. Chirality, 2020, 32, 73-80.	2.6	7
4	Design, synthesis and biological evaluation of water-soluble phenytoin prodrugs considering the substrate recognition ability of human carboxylesterase 1. European Journal of Pharmaceutical Sciences, 2020, 152, 105455.	4.0	5
5	Indole-3-propionic acid has chemical chaperone activity and suppresses endoplasmic reticulum stress-induced neuronal cell death. Biochemical and Biophysical Research Communications, 2019, 517, 623-628.	2.1	24
6	Synthesis and evaluation of haloperidol ester prodrugs metabolically activated by human carboxylesterase. European Journal of Pharmaceutical Sciences, 2019, 132, 125-131.	4.0	11
7	Analysis of carboxylesterase 2 transcript variants in cynomolgus macaque liver. Xenobiotica, 2019, 49, 247-255.	1.1	6
8	Chemical synthesis of an indomethacin ester prodrug and its metabolic activation by human carboxylesterase 1. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 997-1000.	2.2	18
9	Molecular characterization and polymorphisms of butyrylcholinesterase in cynomolgus macaques. Journal of Medical Primatology, 2018, 47, 185-191.	0.6	0
10	Development of a Caco-2 Cell Line Carrying the Human Intestine-Type CES Expression Profile as a Promising Tool for Ester-Containing Drug Permeability Studies. Biological and Pharmaceutical Bulletin, 2018, 41, 697-706.	1.4	9
11	Functional analysis of carboxylesterase in human induced pluripotent stem cell-derived enterocytes. Biochemical and Biophysical Research Communications, 2017, 486, 143-148.	2.1	20
12	Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects. Pharmaceutical Research, 2017, 34, 1584-1600.	3.5	18
13	Synthesis and evaluation of atorvastatin esters as prodrugs metabolically activated by human carboxylesterases. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 921-923.	2.2	14
14	Isolation and characterization of arylacetamide deacetylase in cynomolgus macaques. Journal of Veterinary Medical Science, 2015, 77, 721-724.	0.9	6
15	A New Methodology for Functionalization at the 3-Position of Indoles by a Combination of Boron Lewis Acid with Nitriles. Chemical and Pharmaceutical Bulletin, 2015, 63, 538-545.	1.3	5
16	Analysis of a child who developed abnormal neuropsychiatric symptoms after administration of oseltamivir: a case report. BMC Neurology, 2015, 15, 130.	1.8	15
17	Systematic Identification and Characterization of Carboxylesterases in Cynomolgus Macaques. Drug Metabolism and Disposition, 2014, 42, 2002-2006.	3.3	13
18	The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans. European Journal of Clinical Pharmacology, 2013, 69, 21-30.	1.9	29

#	Article	IF	Citations
19	Gly143Glu polymorphism of the human carboxylesterase1 gene in an Asian population. European Journal of Clinical Pharmacology, 2013, 69, 735-736.	1.9	4
20	Dexamethasone-mediated transcriptional regulation of rat carboxylesterase 2 gene. Xenobiotica, 2012, 42, 614-623.	1.1	4
21	Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mammalian Genome, 2010, 21, 427-441.	2.2	147
22	Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. British Journal of Clinical Pharmacology, 2010, 70, 222-233.	2.4	44
23	The Critical Role of Neutral Cholesterol Ester Hydrolase 1 in Cholesterol Removal From Human Macrophages. Circulation Research, 2010, 107, 1387-1395.	4.5	90
24	Carboxylesterases: structure, function and polymorphism in mammals. Journal of Pesticide Sciences, 2010, 35, 218-228.	1.4	26
25	Prodrug approach using carboxylesterases activity: catalytic properties and gene regulation of carboxylesterase in mammalian tissue. Journal of Pesticide Sciences, 2010, 35, 229-239.	1.4	29
26	Are Non-human Primates Useful Experimental Animals for Pre-clinical Study?. Drug Metabolism and Pharmacokinetics, 2010, 25, 221-222.	2.2	0
27	DNA methylation and its involvement incarboxylesterase 1A1(CES1A1) gene expression. Xenobiotica, 2010, 40, 119-128.	1.1	10
28	Limited Brain Distribution of [3R,4R,5S]-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (Ro 64-0802), a Pharmacologically Active Form of Oseltamivir, by Active Efflux across the Blood-Brain Barrier Mediated by Organic Anion Transporter 3 (Oat3/Slc22a8) and Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4). Drug Metabolism and Disposition, 2009, 37, 315-321.	3.3	121
29	Carboxylesterases: Structure, Function and Polymorphism. Biomolecules and Therapeutics, 2009, 17, 335-347.	2.4	19
30	Functional polymorphisms in carboxylesterase1A2 (CES1A2) gene involves specific protein 1 (Sp1) binding sites. Biochemical and Biophysical Research Communications, 2008, 369, 939-942.	2.1	44
31	Structural Organization and Characterization of the Regulatory Element of the Human Carboxylesterase (CES1A1 and CES1A2) genes. Drug Metabolism and Pharmacokinetics, 2008, 23, 73-84.	2.2	49
32	Structure and Catalytic Properties of Carboxylesterase Isozymes Involved in Metabolic Activation of Prodrugs. Molecules, 2008, 13, 412-431.	3.8	326
33	Fawcettimine-Related Alkaloids fromLycopodiumserratum. Journal of Natural Products, 2007, 70, 1024-1028.	3.0	30
34	Genomic Structure and Transcriptional Regulation of the Rat, Mouse, and Human Carboxylesterase Genes. Drug Metabolism Reviews, 2007, 39, 1-15.	3.6	88
35	Hepatocyte nuclear factor-4Î± plays pivotal roles in the regulation of mouse carboxylesterase 2 gene transcription in mouse liver. Archives of Biochemistry and Biophysics, 2006, 447, 107-117.	3.0	37
36	Species-, sex-, and age-dependent urinary excretion of cauxin, a mammalian carboxylesterase. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2006, 145, 270-277.	1.6	53

#	Article	IF	Citations
37	Structure, Function, and Regulation of Carboxylesterases. , 2006, , 219-231.		280
38	Structure, function and regulation of carboxylesterases. Chemico-Biological Interactions, 2006, 162, 195-211.	4.0	425
39	Substrate Specificity of Carboxylesterase Isozymes and Their Contribution to Hydrolase Activity in Human Liver and Small Intestine. Drug Metabolism and Disposition, 2006, 34, 1734-1741.	3.3	233
40	INVOLVEMENT OF HEPATOCYTE NUCLEAR FACTOR 4Î± IN THE DIFFERENT EXPRESSION LEVEL BETWEEN CYP2C9 AND CYP2C19 IN THE HUMAN LIVER. Drug Metabolism and Disposition, 2006, 34, 1012-1018.	3.3	35
41	Dexamethasone-induced methylprednisolone hemisuccinate hydrolase: Its identification as a member of the rat carboxylesterase 2 family and its unique existence in plasma. Biochemical Pharmacology, 2005, 69, 1287-1297.	4.4	40
42	IDENTIFICATION OF HMG-CoA REDUCTASE INHIBITORS AS ACTIVATORS FOR HUMAN, MOUSE AND RAT CONSTITUTIVE ANDROSTANE RECEPTOR. Drug Metabolism and Disposition, 2005, 33, 924-929.	3.3	68
43	Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenetics and Genomics, 2005, 15, 513-522.	1.5	339
44	IDENTIFICATION OF DI-(2-ETHYLHEXYL) PHTHALATE-INDUCED CARBOXYLESTERASE 1 IN C57BL/6 MOUSE LIVER MICROSOMES: PURIFICATION, CDNA CLONING, AND BACULOVIRUS-MEDIATED EXPRESSION. Drug Metabolism and Disposition, 2004, 32, 1170-1177.	3.3	25
45	Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. Human Molecular Genetics, 2004, 13, 2959-2969.	2.9	49
46	KEY STRUCTURAL FEATURES OF LIGANDS FOR ACTIVATION OF HUMAN PREGNANE X RECEPTOR. Drug Metabolism and Disposition, 2004, 32, 468-472.	3.3	26
47	Synergistic role of specificity proteins and upstream stimulatory factor 1 in transactivation of the mouse carboxylesterase 2/microsomal acylcarnitine hydrolase gene promoter. Biochemical Journal, 2004, 384, 101-110.	3.7	29
48	A Novel Variant Allele of OATP-C (SLCO1B1) Found in a Japanese Patient with Pravastatin-induced Myopathy. Drug Metabolism and Pharmacokinetics, 2004, 19, 453-455.	2.2	84
49	CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver. Hepatology, 2003, 37, 665-673.	7.3	53
50	Metabolism of medroxyprogesterone acetate (MPA) via CYP enzymes in vitro and effect of MPA on bleeding time in female rats in dependence on CYP activity in vivo. Life Sciences, 2003, 73, 3201-3212.	4.3	9
51	Purification, molecular cloning, and functional expression of inducible liver acylcarnitine hydrolase in C57BL/6 mouse, belonging to the carboxylesterase multigene family. Archives of Biochemistry and Biophysics, 2003, 416, 101-109.	3.0	40
52	Evidence for the Involvement of a Pulmonary First-Pass Effect via Carboxylesterase in the Disposition of a Propranolol Ester Derivative after Intravenous Administration. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 1234-1242.	2.5	37
53	Effects of G169R and P34S Substitutions Produced by Mutations ofCYP2D6*14on the Functional Properties of CYP2D6 Expressed in V79 Cells. Drug Metabolism and Disposition, 2002, 30, 1201-1205.	3.3	10
54	Measurement of Carboxylesterase (CES) Activities. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2001, 10, Unit4.7.	1.1	64

#	Article	IF	Citations
55	Purification, Molecular Cloning, and Functional Expression of Dog Liver Microsomal acyl-CoA Hydrolase: A Member of the Carboxylesterase Multigene Family. Archives of Biochemistry and Biophysics, 2001, 389, 245-253.	3.0	26
56	Inactivation of Rat Cytochrome P450 2D Enzyme by a Further Metabolite of 4-Hydroxypropranolol, the Major and Active Metabolite of Propranolol.. Biological and Pharmaceutical Bulletin, 2001, 24, 988-994.	1.4	25
57	High-performance liquid chromatographic analysis of the sulfation of 4-hydroxypropranolol enantiomers by monkey liver cytosol. Chirality, 2001, 13, 140-147.	2.6	9
58	Effects of carbamazepine on the first ovulation in gonadotropin-primed immature female rats. British Journal of Pharmacology, 2001, 134, 1328-1334.	5.4	2
59	Toxicological significance in the cleavage of esterase-Î²-glucuronidase complex in liver microsomes by organophosphorus compounds. Chemico-Biological Interactions, 1999, 119-120, 471-478.	4.0	23
60	cDNA cloning, characterization and stable expression of novel human brain carboxylesterase. FEBS Letters, 1999, 458, 17-22.	2.8	64
61	Analysis of genetic polymorphism on the promoter region of a human liver carboxylesterase gene. Drug Metabolism and Pharmacokinetics, 1999, 14, 94-95.	0.0	0
62	THE MAMMALIAN CARBOXYLESTERASES: From Molecules to Functions. Annual Review of Pharmacology and Toxicology, 1998, 38, 257-288.	9.4	690
63	Synthesis of a new class of camptothecin derivatives, the long-chain fatty acid esters of 10-hydroxycamptothecin, as a potent prodrug candidate, and their in vitro metabolic conversion by carboxylesterases. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 415-418.	2.2	25
64	Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochimica Et Biophysica Acta - General Subjects, 1998, 1380, 297-304.	2.4	59
65	cDNA Cloning and Genomic Organization of Peroxisome Proliferator-Inducible Long-Chain Acyl-CoA Hydrolase from Rat Liver Cytosol. Biochemical and Biophysical Research Communications, 1998, 248, 608-612.	2.1	23
66	Multiplicity and Species Differences of Carboxylesterase Isozymes in Mammals and Humans.. Drug Metabolism and Pharmacokinetics, 1998, 13, 405-417.	0.0	0
67	Species differences in the substrate specificity of carboxylesterase isozymes in mammals and humans. Drug Metabolism and Pharmacokinetics, 1998, 13, 90-91.	0.0	0
68	Molecular Cloning and Expression of cDNAs Encoding Rat Brain and Liver Cytosolic Long-Chain Acyl-CoA Hydrolases. Biochemical and Biophysical Research Communications, 1997, 232, 198-203.	2.1	30
69	Differences in the Induction of Carboxylesterase RL4 in Rat Liver Microsomes by Various Perfluorinated Fatty Acids, Metabolically Inert Derivatives of Fatty Acids.. Biological and Pharmaceutical Bulletin, 1996, 19, 765-767.	1.4	21
70	Molecular aspects of carboxylesterase isoforms in comparison with other esterases. Toxicology Letters, 1995, 82-83, 439-445.	0.8	57
71	CLONING AND EXPRESSION OF cDNA ENCODING CARBOXYLESTERASE ISOZYMES FROM MAMMALS AND HUMANS. Drug Metabolism and Pharmacokinetics, 1995, 10, 138-141.	0.0	0
72	N-Nitrosodiethylamine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced morphological transformation of C3H/10T1/2CL8 cells expressing human cytochrome P450 2A6. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1994, 324, 93-102.	1.1	10

#	Article	IF	Citations
73	Human CYP2A6 activation of 4-(methylnitrosamino)-l-(3-pyridyl)-1-butanone (NNK): mutational specificity in the gpt gene of AS52 cells. Carcinogenesis, 1994, 15, 2859-2866.	2.8	50
74	Metabolic Activation of CPT-11, 7-Ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxycamptothecin, a Novel Antitumor Agent, by Carboxylesterase.. Biological and Pharmaceutical Bulletin, 1994, 17, 662-664.	1.4	171
75	Differential responses of rat hepatic microsomal carboxylesterase isozymes to glucocorticoids and pregnenolone 16Î±-carbonitrile. Biochemical Pharmacology, 1993, 45, 2317-2322.	4.4	32
76	Retroviral mediated expression of human cytochrome P450 2A6 in C3H/10T1/2 cells confers transformability by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Carcinogenesis, 1993, 14, 1421-1427.	2.8	34
77	Multiplicity and Acylation/Deacylation Capability of Liver Microsomal Carboxyl este rase Isozymes in Several Animal Species and Humans. Drug Metabolism and Pharmacokinetics, 1993, 8, 637-640.	0.0	0
78	Changes in Carboxylesterase Isoenzymes of Rat Liver Microsomes during Hepatocarcinogenesis. Japanese Journal of Cancer Research, 1991, 82, 800-806.	1.7	36
79	Characterization of molecular species of liver microsomal carboxylesterases of several animal species and humans. Archives of Biochemistry and Biophysics, 1990, 277, 219-227.	3.0	176
80	Enhancement of the Binding of O-Ethyl O-p-Nitrophenyl 3henylphosphonate (EPNoxon) to Microsomal Carboxylesterase by NAD in vitro. The Japanese Journal of Pharmacology, 1985, 37, 39-44.	1.2	1